Cleavage of HPV-16 E6/E7 mRNA mediated by modified 10-23 deoxyribozymes

Oligonucleotides

Volumn 19, Issue 3, 2009, Pages 233-242

  Reyes Gutiérrez, Pablo ^a   Alvarez Salas, Luis M ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBOZYME; LOCKED NUCLEIC ACID; MESSENGER RNA; PROTEIN E6; PROTEIN E7;

ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SPECIFICITY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; PRIORITY JOURNAL; RNA CLEAVAGE; UTERINE CERVIX CANCER;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA, CATALYTIC; DNA, SINGLE-STRANDED; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 70349267982     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2009.0193     Document Type: Article

References (59)

1. AGRAWAL, S., ZHAO, Q., JIANG, Z., OLIVER, C., GILES, H., HEATH, J., and SEROTA, D. (1997). Toxicologic effects of an oli-godeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev. 7, 575-584.
2. ALVAREZ-SALAS, L.M. (2008). Nucleic acids as therapeutic agents. Curr. Top. Med. Chem. 8, 1379-1404.
3. ALVAREZ-SALAS, L.M., ARPAWONG, T.E., and DIPAOLO, J.A. (1999). Growth inhibition of cervical tumor cells by antisense oli-godeoxynucleotides directed to the human papillomavirus type 16 E6 gene. Antisense Nucleic Acid Drug Dev. 9, 441-450.
4. ALVAREZ-SALAS, L.M., CULLINAN, A.E., SIWKOWSKI, A., HAMPEL, A., and DIPAOLO, J.A. (1998). Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc. Natl. Acad. Sci. USA. 95, 1189-1194.
5. ALVAREZ-SALAS, L.M., and DIPAOLO, J.A. (2007). Molecular approaches to cervical cancer therapy. Curr. Drug Discov. Te c h n o l. 4, 208-219.
6. AQUINO-JARQUIN, G., BENITEZ-HESS, M.L., DIPAOLO, J.A., and ALVAREZ-SALAS, L.M. (2008). A triplex ribozyme expression system based on a single hairpin ribozyme. Oligonucleotides. 18, 213-224.
7. BEALE, G., HOLLINS, A.J., BENBOUBETRA, M., SOHAIL, M., FOX, S.P., BENTER, I., and AKHTAR, S. (2003). Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J. Drug Target. 11, 449-456.
8. BENITEZ-HESS, M.L., DIPAOLO, J.A., and ALVAREZ-SALAS, L.M. (2004). Antisense activity detection by inhibition of f uorescence resonance energy transfer. Luminescence. 19, 85-93.
9. BHINDI, R., FAHMY, R.G., LOWE, H.C., CHESTERMAN, C.N., DASS, C.R., CAIRNS, M.J., SARAVOLAC, E.G., SUN, L.Q., and KHACHIGIAN, L.M. (2007). Brothers in arms. DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am. J. Pathol. 171, 1079-1088.
10. BONDENSGAARD, K., PETERSEN, M., SINGH, S.K., RAJWANSHI, V.K., KUMAR, R., WENGEL, J., and JACOBSEN, J.P. (2000). St r uc t u ra l st ud i e s of LNA:R NA duplexes by N M R: con f o r mat io n s and implications for RNase H activity. Chemistry. 6, 2687-2695.
11. BROWN, A.K., LI, J., PAVOT, C.M., and LU, Y. (2003). A lead-dependent DNAzyme with a two-step mechanism. Biochemistry. 42, 7152-7161.
12. CAIRNS, M.J., HOPKINS, T.M., WITHERINGTON, C., and SUN, L.Q. (2000). The inf uence of arm length asymmetry and base substitution on the activity of the 10-23 DNA enzyme. Antisense Nucleic Acid Drug Dev. 10, 323-332.
13. CAIRNS, M.J., HOPKINS, T.M., WITHERINGTON, C., WANG, L., and SUN, L.Q. (1999). Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotechnol. 17, 480-486.
14. CHAKRABORTI, S., and BANERJEA, A.C. (2003). Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: potential effectiveness against all HIV-1 isolates. Mol. Ther. 7, 817-826.
15. CIESLAK, M., NIEWIAROWSKA, J., NAWROT, M., KOZIOLKIEWICZ, M., STEC, W.J., and CIERNIEWSKI, C.S. (2002). DNAzymes to beta 1 and beta 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in f brin and matrigel. J. Biol. Chem. 277, 6779-6787.
16. CRINELLI, R., BIANCHI, M., GENTILINI, L., and MAGNANI, M. (2002). Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res. 30, 2435-2443.
17. DARFEUILLE, F., HANSEN, J.B., ORUM, H., DI PRIMO, C., and TOULME, J.J. (2004). LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. Nucleic Acids Res. 32, 3101-3107.
18. DASS, C.R., CHOONG, P.F., and KHACHIGIAN, L.M. (2008). DNAzyme technology and cancer therapy: cleave and let die. Mol. Cancer Ther. 7, 243-251.
19. DASS, C.R., SARAVOLAC, E.G., LI, Y., and SUN, L.Q. (2002). Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 12, 289-299.
20. DONINI, S., CLERICI, M., WENGEL, J., VESTER, B., and PERACCHI, A. (2007). The advantages of being locked. Assessing the cleavage of short and long RNAs by locked nucleic acid-containing 8-17 deoxyribozymes. J. Biol. Chem. 282, 35510-35518.
21. DYSON, N., HOWLEY, P.M., MUNGER, K., and HARLOW, E. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 243, 934-937.
22. FLUITER, K., FRIEDEN, M., VREIJLING, J., KOCH, T., and BAAS, F. (2005). Evaluation of LNA-modif ed DNAzymes targeting a single nucleotide polymorphism in the large subunit of RNA poly-merase II. Oligonucleotides. 15, 246-254.
23. FOKINA, A., NOVOPASHINA, D., MESCHANINOVA, M., VOROBJEVA, M., ZENKOVA, M., FRANCOIS, J.C., and VENYAMINOVA, A. (2008). Effective cleavage of structured RNAs by tandems of 10-23 DNAzymes with 3′-modif ed oligo(2′-O- methylribonucleotide)-effectors. Nucleic Acids Symp. Ser. (Oxf.) 52:525-526.
24. GOILA, R., and BANERJEA, A.C. (2001). Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochem. J. 353, 701-708.
25. GUAPILLO, M.R., MARQUEZ-GUTIÉRREZ, M.A., BENITEZ-HESS, M.L., and ALVAREZ-SALAS, L.M. (2006). A bacterial reporter system for the evaluation of antisense oligodeoxynucleotides directed against human papillomavirus type 16 (HPV-16). Arch. Med. Res. 37, 584-592.
26. HENDRY, P., and MCCALL, M. (1996). Unexpected anisotropy in substrate cleavage rates by asymmetric hammerhead ribozymes. Nucleic Acids Res. 24, 2679-2684.
27. JIANG, M., and MILNER, J. (2002). Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene. 21, 6041-6048.
28. KURRECK, J., BIEBER, B., JAHNEL, R., and ERDMANN, V.A. (2002). Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J. Biol. Chem. 277, 7099-7107.
29. LARSSON, R., and NYGREN, P. (1989). A rapid f uorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res. 9, 1111-1119.
30. LI, J., ZHENG, W., KWON, A.H., and LU, Y. (2000). In vitro selection and characterization of a highly eff cient Zn(II)-dependent RNA-cleaving deoxyribozyme. Nucleic Acids Res. 28, 481-488.
31. MARQUEZ-GUTIERREZ, M.A., BENITEZ-HESS, M.L., DIPAOLO, J.A., and ALVAREZ-SALAS, L.M. (2007). Effect of combined anti-sense oligodeoxynucleotides directed against the human papil-lomavirus type 16 on cervical carcinoma cells. Arch. Med. Res. 38, 730-738.
32. MITCHELL, A., DASS, C.R., SUN, L.Q., and KHACHIGIAN, L.M. (2004). Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc f nger transcription factor EGR-1. Nucleic Acids Res. 32, 3065-3069.
33. MUNGER, K., PHELPS, W.C., BUBB, V., HOWLEY, P.M., and SCHLEGEL, R. (1989). The E6 and E7 genes of the human papillo-mavirus type 16 together are necessary and suff cient for transformation of primary human keratinocytes. J. Virol. 63, 4417-4421.
34. NAWROT, B., WIDERA, K., WOJCIK, M., REBOWSKA, B., NOWAK, G., and STEC, W.J. (2007). Mapping of the functional phosphate groups in the catalytic core of deoxyribozyme 10-23. FEBS J. 274, 1062-1072.
35. OTA, N., WARASHINA, M., HIRANO, K., HATANAKA, K., and TAIRA, K. (1998). Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity. Nucleic Acids Res. 26, 3385-3391.
36. PERACCHI, A. (2000). Preferential activation of the 8-17 deoxyri-bozyme by Ca(2+) ions. Evidence for the identity of 8-17 with the catalytic domain of the Mg5 deoxyribozyme. J. Biol. Chem. 275, 11693-11697.
37. PETERSEN, M., and WENGEL, J. (2003). LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol. 21, 74-81.
38. PIRISI, L., YASUMOTO, S., FELLER, M., DONIGER, J., and DIPAOLO, J.A. (1987). Transformation of human f broblasts and keratinocytes with human papillomavirus type 16 DNA. J. Virol. 61, 1061-1066.
39. ROMANI, A.M., and SCARPA, A. (2000). Regulation of cellular magnesium. Front. Biosci. 5, D720-D734.
40. SANTORO, S.W., and JOYCE, G.F. (1997). A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA. 94, 4262-4266.
41. SANTORO, S.W., and JOYCE, G.F. (1998). Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry. 37, 13330-13342.
42. SANTORO, S.W., JOYCE, G.F., SAKTHIVEL, K., GRAMATIKOVA, S., and BARBAS, C.F. (2000). RNA cleavage by a DNA enzyme with extended chemical functionality. J. Am. Chem. Soc. 122, 2433-2439.
43. SCHUBERT, S., GUL, D.C., GRUNERT, H.P., ZEICHHARDT, H., ERDMANN, V.A., and KURRECK, J. (2003). RNA cleaving "10-23" DNAzymes with enhanced stability and activity. Nucleic Acids Res. 31, 5982-5992.
44. SIOUD, M., and IVERSEN, P.O. (2005). Ribozymes, DNAzymes and small interfering RNAs as therapeutics. Curr. Drug Targets 6, 647-653. (Pubitemid 41236548)
45. SOOD, V., GUPTA, N., BANO, A.S., and BANERJEA, A.C. (2007). DNA-enzyme-mediated cleavage of human immunodef cienc virus type 1 Gag RNA is signif cantly augmented by antisense-DNA molecules targeted to hybridize close to the cleavage site. Oligonucleotides. 17, 113-121.
46. TAKAHASHI, H., HAMAZAKI, H., HABU, Y., HAYASHI, M., ABE, T., MIYANO-KUROSAKI, N., and TAKAKU, H. (2004). A new modif ed DNA enzyme that targets inf uenza virus A mRNA inhibits viral infection in cultured cells. FEBS Lett. 560, 69-74.
47. TAN, T.M., and TING, R.C. (1995). In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res. 55, 4599-4605.
48. TOYODA, T., IMAMURA, Y., TAKAKU, H., KASHIWAGI, T., HARA, K., IWAHASHI, J., OHTSU, Y., TSUMURA, N., KATO, H., and HA MADA, N. (20 0 0). I n h ibit io n of i n f uenza virus replication in cultured cells by RNA-cleaving DNA enzyme. FEBS Lett. 481, 113-116.
49. TREPANIER, J., TANNER, J.E., MOMPARLER, R.L., LE, O.N., ALVAREZ, F., and ALFIERI, C. (2006). Cleavage of intracellu-lar hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J. Viral. Hepat. 13, 131-138.
50. VENTURINI, F., BRASPENNING, J., HOMANN, M., GISSMANN, L., and SCZAKIEL, G. (1999). Kinetic selection of HPV 16 E6/ E7-directed antisense nucleic acids: anti-proliferative effects on HPV 16-transformed cells. Nucleic Acids Res. 27, 1585-1592.
51. VESTER, B., HANSEN, L.H., LUNDBERG, L.B., BABU, B.R., SORENSEN, M.D., WENGEL, J., and DOUTHWAITE, S. (2006). Locked nucleoside analogues expand the potential of DNAzymes to cleave structured RNA targets. BMC. Mol. Biol. 7, 19-28.
52. VESTER, B., LUNDBERG, L.B., SORENSEN, M.D., BABU, B.R., DOUTHWAITE, S., and WENGEL, J. (2002). LNAzymes: incorporation of LNA-type monomers into DNAzymes markedly increases RNA cleavage. J. Am. Chem. Soc. 124, 13682-13683.
53. VESTER, B., LUNDBERG, L.B., SORENSEN, M.D., BABU, B.R., DOUTHWAITE, S., and WENGEL, J. (2004). Improved RNA cleavage by LNAzyme derivatives of DNAzymes. Biochem. Soc. Tra ns. 32, 37-40.
54. WAHLESTEDT, C., SALMI, P., GOOD, L., KELA, J., JOHNSSON, T., HOKFELT, T., BROBERGER, C., PORRECA, F., LAI, J., REN, K., OSSIPOV, M., KOSHKIN, A., JAKOBSEN, N., SKOUV, J., OERUM, H., JACOBSEN, M.H., and WENGEL, J. (2000). Potent and non-toxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA. 97, 5633-5638.
55. WARASHINA, M., KUWABARA, T., NAKAMATSU, Y., and TAIRA, K. (1999). Extremely high and specif c activity of DNA enzymes in cells with a Philadelphia chromosome. Chem. Biol. 6, 237-250.
56. WERNESS, B.A., LEVINE, A.J., and HOWLEY, P.M. (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 248, 76-79.
57. WU, Y., YU, L., MCMAHON, R., ROSSI, J.J., FORMAN, S.J., and SNYDER, D.S. (1999). Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum. Gene Ther. 10, 2847-2857.
58. ZABOROWSKA, Z., FURSTE, J.P., ERDMANN, V.A., and KURRECK, J. (2002). Sequence requirements in the catalytic core of the "10-23" DNA enzyme. J. Biol. Chem. 277, 40617-40622.
59. ZUR HAUSEN, H. (1996). Papillomavirus infections a major cause of human cancers. Biochim. Biophys. Acta 1288, F55-F78. (Pubitemid 26335492)